Analysts have been eager to weigh in on the Healthcare sector with new ratings on uniQure (QURE) and Gilead Sciences (GILD).
uniQure (QURE)
Mizuho Securities analyst Difei Yang reiterated a Hold rating on uniQure today and set a price target of $46.00. The company’s shares closed last Tuesday at $42.18.
According to TipRanks.com, Yang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.8% and a 30.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Revance Therapeutics.
Currently, the analyst consensus on uniQure is a Strong Buy with an average price target of $65.75.
See today’s analyst top recommended stocks >>
Gilead Sciences (GILD)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences today and set a price target of $81.00. The company’s shares closed last Tuesday at $60.01, close to its 52-week low of $59.40.
According to TipRanks.com, Syed ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.0% and a 43.8% success rate. Syed covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Unity Biotechnology, and Wave Life Sciences.
Currently, the analyst consensus on Gilead Sciences is a Moderate Buy with an average price target of $79.38, a 32.7% upside from current levels. In a report issued on October 16, Citigroup also maintained a Buy rating on the stock with a $80.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GILD:
